Drug Trial Radar · NCT07904130
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Oct 9, 2026
Primary completion
Oct 1, 2028
Study completion Oct 1, 2029
Sponsor
- Lead sponsor
- West China HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
P (Population): Patients with advanced colorectal cancer who have failed at least two prior lines of therapy. I (Intervention): Radiotherapy, immunotherapy, and fruquintinib. C (Comparator): Single-arm study with no control group. O (Outcomes): Safety, tolerability, and preliminary efficacy of the combination treatment. S (Study design): This is a phase II, single-arm clinical study. Radiotherapy will be delivered at 25-50 Gy in 5 fractions, including dose schedules of 40 Gy in 5 fractions and 50 Gy in 5 fractions, combined with fixed-dose immunotherapy and fruquintinib. The study plans to enroll 32 participants.
Conditions
- Colo-rectal Cancer
Interventions
Personalized ultrafractionated stereotactic adaptive radiotherapyRadiation
Radiotherapy will be delivered at 25-50 Gy in 5 fractions, including dose schedules of 40 Gy in 5 fractions and 50 Gy in 5 fractions
ImmunotherapyDrug
Finotonlimab 200 mg administered once every 21 days; each treatment cycle is 21 days
Target TherapyDrug
Fruquintinib 5 mg orally once daily for 14 consecutive days, followed by a 7-day treatment-free interval; each treatment cycle is 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From the date of first administration of study treatment to the date of first documented tumor progression or death from any cause, whichever occurs first,assessed up to 5 years.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.